Background Information
Cancer Research Partnerships at
Colorado State University
Colorado Cancer Consortium
Colorado State University's cancer researchers partner with all institutions with major cancer research efforts in the region through the Colorado Cancer Consortium. This partnership includes Colorado State University, University of Colorado Health Sciences Center, a National Cancer Institute-designated Comprehensive Cancer Center, and with University of Colorado-Boulder and National Jewish Hospital.
Canine Comparative Oncology and Genomics Consortium
In 2004, a group of veterinary and medical oncologists, pathologists, surgeons, geneticists and molecular and cellular biologists joined together to form the CCOGC. This group facilitates strategic partnerships and collaborations focusing cancer in dogs. Now that the canine genome is available, a repository of tissues, normal and tumor, from tumor-bearing dogs has been identified as an essential need. The CCOGC Biospecimen Repository was formed with the Animal Cancer Center being an inaugural contributor to this tissue archiving effort. The CCOGC Biospecimen Repository will work with groups focused on animal health as well as groups interested in learning more about human disease through comparative oncology from the study of canine cancers.
Mayo Clinic
The university and Mayo Clinic have a multi-year biomedically focused research agreement to collaboratively develop oncology and infectious disease therapeutics, combining significant expertise in comparative oncology and disease treatments. Colorado State will be only the second university with which Mayo Clinic is collaborating on research and education initiatives at its Scottsdale, Ariz., campus. The collaboration will identify research and educational initiatives for vaccinology, oncology and infectious disease therapies.
Comparative Oncology Trial Consortium
This is an initiative of the National Cancer Institute's Comparative Oncology program that recognizes that spontaneous cancer in pets is a significant and relevant model for testing new cancer treatments. In cooperation with National Cancer Institute investigators, academic institutions and the pharmaceutical industry clinical trials of new therapeutic agents and treatment concepts will be conducted. The Colorado State University Animal Cancer Center participates as a primary clinical trials location and academic collaborator in the COTC.
Children's Oncology Group
This national group coordinates and formulates policy and clinical trials to benefit children with cancer in the United States. The group is now using pet animal cancer models in partnerships with the Colorado State University Animal Cancer Center in exploratory or confirmatory clinical trials with relevance to childhood cancer.
Limb Preservation Institute
Research and development within the Animal Cancer Center has a long history with this group and is expanding to develop a comprehensive consortium in musculoskeletal biology and oncology with Colorado State as the lead institution.
AlloSource
AlloSource is one of the nation's largest non-profit providers of human bone and soft tissue allografts. The Animal Cancer Center and Allosource have established an innovative umbrella research agreement fostering a fast-track avenue for intellectual exchange and hypothesis-driven research of preclinical allograft and device testing, efficacy testing, safety studies and product innovation. The goal of this relationship is to improve clinical outcome and safety for human tissue allograft recipients.
NASA Specialized Center of Research in Leukemia
Colorado State University is the leading institution of this center, which includes collaborators M.D. Anderson Cancer Center, Baylor College of Medicine, U.T. Southwestern Medical Center, Promega Corp. and the Medical Research Council of Oxford, UK.
Varian Biosynergy
The Colorado State University cancer research program and Varian have recently established a funded partnership to help the Animal Cancer Center develop into a Center of Excellence for the development and testing of new approaches combining chemotherapy, immunotherapy, molecular biology and radiation therapy for cancer treatment.
University of Colorado Comprehensive Cancer Center
Dr. Dan Gustafson, a professor in Colorado State University's Department of Clinical Sciences, is director of the Core Pharmacology Lab for the University of Colorado Cancer Comprehensive Center and conducts research specific to developmental therapeutics at Colorado State's Animal Cancer Center. Colorado State University is an affiliate member of the University of Colorado Cancer Center through direct involvement in the Core Pharmacology Lab.